Small Molecule for SARS-CoV-2 Vaccine Complications
Post-vaccination complications
Key Facts
About Genekam Biotechnology
Genekam Biotechnology AG is a privately held, revenue-generating German biotech focused on infectious disease diagnostics and early-stage therapeutic development. Its core business is the sale of CE-marked, IVDR-compliant PCR test kits for pathogens of immediate public health concern, such as avian influenza H5N1/H5N2 and Nipah virus, allowing it to respond rapidly to outbreaks. The company is also exploring therapeutic avenues, including human monoclonal antibodies against H5N1 and a small molecule for SARS-CoV-2 vaccine complications, though these remain in pre-clinical research. With a small, multidisciplinary team, Genekam leverages its diagnostic platform to generate revenue while funding speculative R&D in novel biologics and treatments.
View full company profile